Macrophage Stimulating Protein Receptor - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H1 2019’, provides in depth analysis on Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology and Metabolic Disorders under development targeting Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1)

- The report reviews Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Advenchen Laboratories LLC

Aslan Pharmaceuticals Ltd

Bristol-Myers Squibb Co

Eli Lilly and Co

Lead Discovery Center GmbH

Pfizer Inc

SignalChem Lifesciences Corp

Advenchen Laboratories LLC

Aslan Pharmaceuticals Ltd

Bristol-Myers Squibb Co

Eli Lilly and Co

Lead Discovery Center GmbH

Pfizer Inc

SignalChem Lifesciences Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) – Overview

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) – Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

Aslan Pharmaceuticals Ltd

Bristol-Myers Squibb Co

Eli Lilly and Co

Lead Discovery Center GmbH

Pfizer Inc

SignalChem Lifesciences Corp

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) – Drug Profiles

AL-2846 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASLAN-005 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-777607 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crizotinib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

merestinib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RON Kinase for Pancreatic Cancer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MST1R for Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) – Dormant Products

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) – Discontinued Products

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) – Product Development Milestones

Featured News & Press Releases

Nov 15, 2018: Crizotinib Plus Radiation May Reduce NF2-Related Hearing Loss

Jul 26, 2018: NICE Issues Technology Appraisal Guidance on Crizotinib for Treating ROS1-positive Advanced NSCLC

Jun 11, 2018: Pfizer’s Xalkori accepted for use in NHS Scotland

Jun 02, 2018: Updated Phase 1 results of crizotinib against MET-amplified non-small cell lung cancer

May 29, 2018: Pfizer's XALKORI (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications

Apr 15, 2018: Crizotinib Yielded a High Objective Response Rate for Adult Patients With ALK-positive Inflammatory Myofibroblastic Tumor

Apr 02, 2018: Lung cancer drug shows promise as targeted therapy for thousands with breast cancer

Feb 05, 2018: Adding crizotinib to radiation therapy may help preserve hearing in patients with NF2

Dec 08, 2017: Largest trial ever performed in alveolar soft part sarcoma: results published

Nov 14, 2017: XALKORI Approved by Health Canada for the Treatment of Patients with ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sep 20, 2017: Publication of EORTC 90101 “CREATE” Phase II trial

Sep 11, 2017: Pfizer Presents Overall Survival Data of XALKORI in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

Aug 30, 2017: New approach to genetic testing matches lung cancer patient with life-saving drug

Jun 02, 2017: OxOnc Announces that Co-development Partner Has Received Approval in Japan and Taiwan for Crizotinib (Xalkori) as a First-line Treatment for Patients with ROS1-Positive Non-Small Cell Lung Cancer

Feb 15, 2017: ASLAN Pharmaceuticals’ new ASLAN002 (BMS777607) phase 1 data published in Science Translational Medicine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Advenchen Laboratories LLC, H1 2019

Pipeline by Aslan Pharmaceuticals Ltd, H1 2019

Pipeline by Bristol-Myers Squibb Co, H1 2019

Pipeline by Eli Lilly and Co, H1 2019

Pipeline by Lead Discovery Center GmbH, H1 2019

Pipeline by Pfizer Inc, H1 2019

Pipeline by SignalChem Lifesciences Corp, H1 2019

Dormant Projects, H1 2019

Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports